TransThera Sciences (Nanjing) (2617) Fundamentals 2026 — Revenue Analysis | SniperIQ

0.90 on the HKSE. This SniperIQ fundamentals page covers TransThera Sciences (Nanjing)'s valuation, profitability (net margin 0.0%), balance-sheet quality, and AI signal context — from live market data, research only.

Full research coverage

• 8-Quarter Revenue & Margin Trend
• Debt Maturity & Coverage
• Peer Valuation Comparison
• Free Cash Flow & Owner Earnings
• AI Signal + Institutional Flow
• DCF Valuation Model

Frequently Asked Questions

What is TransThera Sciences (Nanjing)'s market cap?

TransThera Sciences (Nanjing) (2617) has a market capitalization of approximately HK$4.3B, trading at HK

0.90 on the HKSE. Market cap moves with the live share price.

What is TransThera Sciences (Nanjing)'s P/E ratio?

TransThera Sciences (Nanjing)'s trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is TransThera Sciences (Nanjing)?

TransThera Sciences (Nanjing) runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

Does TransThera Sciences (Nanjing) pay a dividend?

TransThera Sciences (Nanjing) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is TransThera Sciences (Nanjing) financially healthy?

TransThera Sciences (Nanjing) carries a debt-to-equity ratio of 0.00x and a current ratio of 3.87x, with a market beta of 6.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is TransThera Sciences (Nanjing) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For TransThera Sciences (Nanjing) (2617) the key facts are: market cap HK$4.3B, 52-week range 9.01-679.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.